Bunaftine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Bunaftine
Accession Number
DB13652
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
GH09PRQ3FU
CAS number
32421-46-8
Weight
Average: 326.484
Monoisotopic: 326.235813594
Chemical Formula
C21H30N2O
InChI Key
WWGZXRYELYWJBD-UHFFFAOYSA-N
InChI
InChI=1S/C21H30N2O/c1-4-7-15-23(17-16-22(5-2)6-3)21(24)20-14-10-12-18-11-8-9-13-19(18)20/h8-14H,4-7,15-17H2,1-3H3
IUPAC Name
N-butyl-N-[2-(diethylamino)ethyl]naphthalene-1-carboxamide
SMILES
CCCCN(CCN(CC)CC)C(=O)C1=C2C=CC=CC2=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Bunaftine.
AcebutololThe risk or severity of QTc prolongation can be increased when Acebutolol is combined with Bunaftine.
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Bunaftine.
AcetyldigitoxinAcetyldigitoxin may increase the arrhythmogenic activities of Bunaftine.
AcetyldigoxinThe risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Bunaftine.
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Bunaftine.
AdenosineThe risk or severity of QTc prolongation can be increased when Adenosine is combined with Bunaftine.
AgmatineAgmatine may increase the arrhythmogenic activities of Bunaftine.
AjmalineThe risk or severity of QTc prolongation can be increased when Ajmaline is combined with Bunaftine.
AlfuzosinThe risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Bunaftine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
33233
ChEBI
135392
ChEMBL
CHEMBL2104200
Wikipedia
Bunaftine
ATC Codes
C01BD03 — Bunaftine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0147 mg/mLALOGPS
logP4.84ALOGPS
logP4.32ChemAxon
logS-4.4ALOGPS
pKa (Strongest Basic)9.01ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area23.55 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity102.77 m3·mol-1ChemAxon
Polarizability38.91 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenecarboxamides. These are compounds containing a naphthalene moiety, which bears a carboxylic acid amide group at one or more positions. Naphthalene is a bicyclic compound that is made up of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Naphthalenecarboxylic acids and derivatives
Direct Parent
Naphthalenecarboxamides
Alternative Parents
Tertiary carboxylic acid amides / Trialkylamines / Amino acids and derivatives / Organopnictogen compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
1-naphthalenecarboxamide / Tertiary carboxylic acid amide / Amino acid or derivatives / Carboxamide group / Tertiary amine / Tertiary aliphatic amine / Carboxylic acid derivative / Organic oxide / Organooxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:46 / Updated on May 01, 2019 13:13